Advertisement
Advertisement
QGEN
QIAGEN N.V.
43.23
USDSponsored
+0.23
+0.53%
Aug 13, 16:00 UTC -4
Closed
After-Market
43.00
-0.23
-0.53%
QGEN Earnings Reports
Positive Surprise Ratio
QGEN beat 32 of 42 last estimates.
76%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$548.45M
/$0.63
Implied change from Q2 26 (Revenue/ EPS)
+2.51%
/+1.61%
Implied change from Q3 25 (Revenue/ EPS)
+2.98%
/-1.56%
QIAGEN N.V. earnings per share and revenue
On Aug 05, 2026, QGEN reported earnings of 0.62 USD per share (EPS) for Q2 26, beating the estimate of 0.61 USD, resulting in a 1.59% surprise. Revenue reached 535.04 million, compared to an expected 538.03 million, with a -0.56% difference. The market reacted with a -0.52% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of 0.63 USD, with revenue projected to reach 548.45 million USD, implying an increase of 1.61% EPS, and increase of 2.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.18
Actual
-$1.44
Surprise
-21.23%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
MiNK Therapeutics, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.61
Actual
-$0.62
Surprise
-1.31%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
FAQ
What were QIAGEN N.V.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, QIAGEN N.V. reported EPS of $0.62, beating estimates by 1.59%, and revenue of $535.04M, -0.56% below expectations.
How did the market react to QIAGEN N.V.'s Q2 2026 earnings?
The stock price moved down -0.52%, changed from $41.95 before the earnings release to $41.73 the day after.
When is QIAGEN N.V. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for QIAGEN N.V.'s next earnings report?
Based on 12
analysts, QIAGEN N.V. is expected to report EPS of $0.63 and revenue of $548.45M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement